Analyst Research

Report Title Price
Provider: Sadif Analytics Prime
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: Sadif Analytics Prime
$25.00
Provider: Thomson Reuters StreetEvents
$75.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Ipsen SA's Dysport Receives Approval in Canada; Dysport to Be Marketed in Canada by Medicis Aesthetics Canada


Tuesday, 9 Apr 2013 01:30am EDT 

Ipsen SA announced that Health Canada has granted a marketing authorization for Dysport (Botulinum toxin type A for injection) for the temporary improvement in the appearance of moderate to severe frown lines (glabellar lines) in adult patients younger than 65 years of age. Medicis Aesthetics Canada, a division of Valeant Pharmaceuticals, will market Dysport for use in aesthetic medicine in Canada. Launch is expected in April 2013. Financial terms were not disclosed. 

Company Quote

41.965
-0.055 -0.13%
20 Nov 2014